Amgen in its $4 billion acquisition of ChemoCentryx

On August 3, 2022, Amgen Inc. and ChemoCentryx, Inc., a biopharmaceutical company focused on orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, for a total transaction value of approximately $4 billion.

Wachtell, Lipton, Rosen & Katz served as legal advisor to Amgen.